Compare Abeona Therapeutics Inc (ABEO) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Raytheon Technologies Corp — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Raytheon Technologies Corp trades at $194.82 (market cap $270.48B). The key difference: Raytheon Technologies Corp is far larger — about 724.5× Abeona Therapeutics Inc's market cap, and Raytheon Technologies Corp pays a 1.45% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | RTX | |
|---|---|---|
Market Cap | $373.32M | $270.48B |
Sector | Health | Industrials |
52-Week High | $7.23 | $212.16 |
52-Week Low | $4.17 | $144.91 |
Enterprise Value | $228.22M | $302.60B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
RTX trades at $201.37, up 1.06% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a $515 million Navy contract for SPY-6 radars highlight operational momentum. Revenue grew to $88.6 billion in 2025, with net income margin improving to 8.03%. The stock is near its consensus price target of $213, with no sell ratings among 26 analysts.
The outlook is positive, driven by defense contract wins and earnings growth, but risks include high valuation multiples and geopolitical dependencies. Upside potential exists if the company maintains its earnings beat streak and capitalizes on increased defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
